Combined injectable contraceptive

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Combined Injectable Contraceptive
Background
Birth control type Hormonal
First use about 1980
Failure rates (first year)
Perfect use 0-0.2[1]%
Typical use ?
Usage
Duration effect 1 month
User reminders ?
Advantages and disadvantages
STD protection No
Benefits Especially good if poor pill compliance.

Combined injectable contraceptive (CIC) monthly injection of progesterone and estradiol taken to inhibit fertility. Brand names include Cyclofem, Novafem, Mesigyna, Lunelle and Cyclo-Provera.

DMPA is a different injectable contraceptive, containing just a progestin, given every three months.

History[edit]

  • October 5, 2000, Pharmacia received FDA approval for Lunelle Monthly Contraceptive Injection.[1]
  • April 2003, Pharmacia acquired by Pfizer (makers of Depo-Provera (DMPA)).
  • October 2003, Lunelle was discontinued in the U.S.

Use and packaging[edit]

Administered by intramuscular injection into the deltoid, gluteus maximus, or anterior thigh.[1] Ideally administered every 28 to 30 days, though demonstrated to be effective up to 33 days.[1]

Side-effects[edit]

The most prominent side effects are menstrual irregularities during the first 3 to 6 months of use.[1]

Formulations[edit]


See also[edit]

Footnotes[edit]

  1. ^ a b c d e f "FDA Approves Combined Monthly Injectable Contraceptive". Contraception Report 12 (3). 2001. [dead link]